EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Increase in Full-Length Dystrophin by Exon Skipping in Duchenne Muscular Dystrophy Patients with Single Exon Duplications: An Open-label Study

Stefan Nicolau, Jyoti Malhotra, Maryann Kaler, Pamela Magistrado-Coxen, Megan A Iammarino, Natalie F Reash, Emma C Frair, Saranga Wijeratne, Benjamin J Kelly, Peter White, Linda P Lowes, Megan A Waldrop und 1 weitere

Journal of Neuromuscular Diseases · 2024

DOI: 10.3233/jnd-230107 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Neuromuscular Diseases, 2024. Verfasst von Stefan Nicolau und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, USA. Hauptthemen laut MEDLINE: Dystrophin, Exons, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Single exon duplications account for disease in a minority of Duchenne muscular dystrophy patients. Exon skipping in these patients has the potential to be highly therapeutic through restoration of full-length dystrophin expression. We conducted a 48-week open label study of casimersen and golodirsen in 3 subjects with an exon 45 or 53 duplication. Two subjects (aged 18 and 23 years) were non-ambulatory at baseline. Upper limb, pulmonary, and cardiac function appeared stable in the 2 subjects in whom they could be evaluated. Dystrophin expression increased from 0.94 % ±0.59% (mean±SD) of normal to 5.1% ±2.9% by western blot. Percent dystrophin positive fibers also rose from 14% ±17% at baseline to 50% ±42% . Our results provide initial evidence that the use of exon-skipping drugs may increase dystrophin levels in patients with single-exon duplications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DystrophinExonsMuscular Dystrophy, DuchenneAdolescentHumansMaleYoung AdultGene DuplicationOligonucleotidesMorpholinos

Stichwörter der Autor:innen

Muscular dystrophyantisenseclinical trialduchennedystrophinoligonucleotides

Substanzen

DystrophingolodirsenOligonucleotidesMorpholinos

Autor:innen und Institutionen

  • Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, USA.
  • Sarepta Therapeutics Inc., Cambridge, MA, USA.
  • Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.
  • Department of Pediatrics, The Ohio State University, Columbus, OH, USA.
  • >Department of Neurology>, The Ohio State University, Columbus, OH, USA.

Zitieren

APA

Nicolau, S., Malhotra, J., Kaler, M., Magistrado-Coxen, P., Iammarino, M. A., Reash, N. F., Frair, E. C., Wijeratne, S., Kelly, B. J., White, P., Lowes, L. P., Waldrop, M. A., & Flanigan, K. M. (2024). Increase in Full-Length Dystrophin by Exon Skipping in Duchenne Muscular Dystrophy Patients with Single Exon Duplications: An Open-label Study. Journal of Neuromuscular Diseases. https://doi.org/10.3233/jnd-230107

Vancouver

Nicolau S, Malhotra J, Kaler M, Magistrado-Coxen P, Iammarino MA, Reash NF, et al. Increase in Full-Length Dystrophin by Exon Skipping in Duchenne Muscular Dystrophy Patients with Single Exon Duplications: An Open-label Study. Journal of Neuromuscular Diseases. 2024. doi:10.3233/jnd-230107

BibTeX
@article{Nicolau2024,
  author = {Nicolau, Stefan and Malhotra, Jyoti and Kaler, Maryann and Magistrado-Coxen, Pamela and Iammarino, Megan A and Reash, Natalie F and Frair, Emma C and Wijeratne, Saranga and Kelly, Benjamin J and White, Peter and Lowes, Linda P and Waldrop, Megan A and Flanigan, Kevin M},
  title = {Increase in Full-Length Dystrophin by Exon Skipping in Duchenne Muscular Dystrophy Patients with Single Exon Duplications: An Open-label Study},
  journal = {Journal of Neuromuscular Diseases},
  year = {2024},
  doi = {10.3233/jnd-230107}
}
Kostenlos starten →